Textbook of Bladder CancerSeth P. Lerner, Mark Schoenberg, Cora Sternberg CRC Press, 17 sty 2006 - 816 A comprehensive reference, drawing on the expertise of international leaders in the field, this text covers everything from epidemiology, pathology, and diagnosis to the treatment of both superficial and invasive bladder cancers . The book contains over 300 to quality illustrations. |
Spis treści
Epidemiology of bladder cancer | 3 |
Occupational risk factors | 13 |
Familial bladder cancer | 19 |
Genetic susceptibility to bladder cancer | 30 |
Pathology | 37 |
WHOISUP grading system | 63 |
contemporary consensus | 71 |
Nonurothelial tumors | 85 |
Cystectomy in the female | 471 |
Nervesparing radical cystectomy | 479 |
Laparoscopic radical cystectomy and urinary diversion | 487 |
Role of extended pelvic lymphadenectomy | 499 |
Role of sentinel node detection | 507 |
Management of the urethra in the cystectomy patient | 515 |
Role of radical cystectomy in patients with unresectable | 525 |
Primary bladder sparing therapy | 533 |
Diagnosis | 172 |
Cystoscopy | 179 |
Florescence endoscopy | 187 |
Cytology and DNA ploidy | 207 |
Staging | 229 |
Etiology and management of urothelial tumors of the renal | 237 |
Early detection for bladder cancer | 257 |
Natural history of stages Ta T1 and Tis urothelial cancer in | 267 |
Risk stratification of Ta Tis T1 cancer | 281 |
Issues in staging of Ta Tis T1 bladder cancers | 287 |
Transurethral resection of bladder tumors | 299 |
Laser ablation and other technology | 311 |
Perioperative instillation of chemotherapeutic drugs | 329 |
The role of intravesical chemotherapy in the treatment | 335 |
BCG | 353 |
Mode of action of BCG and rationale for combination | 359 |
ethical issues | 367 |
Photodynamic therapy | 375 |
G3T1 bladder carcinoma | 387 |
What to do when BCG fails | 397 |
T24 | 427 |
Selection and perioperative management of patients | 433 |
Radical cystectomytechnique and outcomes | 445 |
Partial cystectomy | 543 |
Optimal radiotherapy for bladder cancer | 551 |
Trimodality therapy in the management of muscleinvasive | 569 |
Urinary tract reconstruction | 579 |
Continent cutaneous diversion | 595 |
Noncontinent urinary diversion | 607 |
Metabolic aspects of diversion | 615 |
Psychosocial and qualityoflife issues | 631 |
Tissue engineering of the bladder | 637 |
Treatment of regionally advanced | 645 |
Neoadjuvant chemotherapy in the treatment | 657 |
Adjuvant chemotherapy for invasive bladder cancer | 665 |
Treatment of metastatic cancer | 671 |
Special considerations in the elderly patient | 683 |
Targeted therapy for bladder cancer | 695 |
Treatment of nonTCC | 721 |
Treatment of squamous cell carcinoma | 729 |
Pediatric bladder tumours | 735 |
Ancillary | 749 |
Support groups | 755 |
| 763 | |
Inne wydania - Wyświetl wszystko
Kluczowe wyrazy i wyrażenia
analysis associated bacillus Calmette-Guérin biomarkers biopsy bladder cancer bladder carcinoma bladder tumors bladder wall bowel Cancer Res carcinogens carcinoma in situ chemotherapy chromosome clinical colon cystoscopy cytology detection diagnosis disease dissection distal evaluation exposure expression factors follow-up gene genetic grade Herr HW high-grade histologic human bladder ileal increased intravesical invasive bladder cancer lamina propria laparoscopic laser lesions low-grade lymph node malignant markers metastases mitomycin molecular mucosa muscle muscle-invasive muscularis mutations neobladder neoplasms nephroureterectomy normal Oncogene orthotopic outcome papillary tumors partial cystectomy Pathol pathologic pathways pelvic polymorphism postoperative preoperative primary prognostic progression prostate protein radiation radical cystectomy radiotherapy recurrence rate renal reported reservoir response risk sensitivity specimens stage superficial bladder cancer surgery surgical survival technique tissue transitional cell carcinoma transurethral resection treatment ureter urethra urinary bladder urinary diversion urinary tract urine Urol Urology urothelial urothelial cancer urothelial carcinoma urothelium